GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the … – MarketWatch

GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the
MarketWatch
20, 2014 /PRNewswire/ — GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic …

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.